In this series of exercises, you will develop a PBPK model of the sodium/glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin in pre-clinical species rat, dog, and monkey. You will then translate the models to humans to predict intravenous (iv) administration of dapagliflozin. The hands-on describes the development of a simplified version of the dapagliflozin PBPK model.
